KRAS and cancer: Considering the selectivity of VC in inducing an oxidizing impact in KRAS-mutant cancer cells, there were several cancer clinical trials initiated to test a high dose of VC or its combination with other common cancer drugs such as gemcitabine, paclitaxel, cisplatin, or docetaxel, and in some cases including the radiation treatment [102].